Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.41 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.40 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | VNN1 | O95497 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4951642 | 0.86 | EPHX2 (0.47) | EPHX2LOXL2ABCB1PPARADPP4 | |
| SCHEMBL5346390 | 0.85 | LOXL2 (0.53) | EPHX2LOXL2SCN8ACACNA1GCACNA1B | |
| SCHEMBL29860036 | 0.84 | SCN8A (0.47) | ABCB1SCN8AVNN1 | |
| SCHEMBL14205020 | 0.82 | KMT2A (0.46) | HTTS1PR1 | |
| SCHEMBL13662612 | 0.82 | ATM (0.44) | CA12CA1S1PR1CA7 | |
| SCHEMBL8421187 | 0.82 | VSIR (0.44) | SCN8ACA1CA2S1PR1 | |
| SCHEMBL15876277 | 0.82 | MTNR1A (0.42) | CA12CA1S1PR1CA7 | |
| SCHEMBL24022857 | 0.81 | ABCB1 (0.40) | EPHX2ABCB1SCN8AS1PR1 | |
| SCHEMBL6163414 | 0.81 | LOXL2 (0.49) | EPHX2LOXL2SCN8ACACNA1GCACNA1B | |
| SCHEMBL8139519 | 0.81 | TPSAB1 (0.45) | LOXL2S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240182382-A1 | ALIPHATIC 18F-RADIOLABELING OF A TETRAZINE PRECURSOR | UNIV COPENHAGEN (DK) | 2024-06-06 | — | — | US | disclosed |
| US-20240166612-A1 | ARYLTHIOETHER ACETAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | X-BIOTIX THERAPEUTICS, INC. | 2024-05-23 | — | — | US | disclosed |
| EP-4305009-A2 | ALIPHATIC 18F-RADIOLABELING OF A TETRAZINE PRECURSOR | University of Copenhagen (DK) | 2024-01-17 | — | — | EP | disclosed |
| EP-4294523-A1 | ARYLTHIOETHER ACETAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | X-Biotix Therapeutics, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| WO-2022189304-A2 | ALIPHATIC 18F-RADIOLABELING OF A TETRAZINE PRECURSOR | UNIVERSITY OF COPENHAGEN (DK) | 2022-09-15 | — | — | WO | disclosed |
| EP-4056546-A1 | ALIPHATIC 18F-RADIOLABELING OF A TETRAZINE PRECURSOR | University of Copenhagen (DK) | 2022-09-14 | — | — | EP | disclosed |
| WO-2022178228-A1 | ARYLTHIOETHER ACETAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | X-BIOTIX THERAPEUTICS, INC. (US) | 2022-08-25 | — | — | WO | disclosed |
| EP-2414341-B1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2017-09-13 | — | — | EP | disclosed |
| US-9700543-B2 | GLP-1 receptor stabilizers and modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-07-11 | — | — | US | disclosed |
| US-9700543-B2 | GLP-1 receptor stabilizers and modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-07-11 | — | — | US | disclosed |
| US-20120035226-A1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2012-02-09 | — | — | US | disclosed |
| EP-2414341-A2 | OXADIAZOLE DERIVATIVES | Merck Serono SA (CH) | 2012-02-08 | — | — | EP | disclosed |
| EP-2414342-A1 | OXADIAZOLE DERIVATIVES | Merck Serono S.A. (CH) | 2012-02-08 | — | — | EP | disclosed |
| US-20120022109-A1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2012-01-26 | — | — | US | disclosed |
| WO-2010115751-A2 | OXADIAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010112461-A1 | OXADIAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2010-10-07 | — | — | WO | disclosed |
| US-6646124-B2 | Gamma-aminobutyric acid (GABA) agonists, antagonists or inverse agonists; treatment of anxiety, Down Syndrome, sleep, cognitive and seizure disorders, and overdose with benzodiazepine drugs | NEUROGEN CORPORATION | 2003-11-11 | — | — | US | disclosed |
| US-20020156280-A1 | Substituted 4-oxo-napthyridine-3-carboxamides: GABA brain receptor ligands | NEUROGEN CORPORATION, CORPORATION OF THE STATE OF DELAWARE | 2002-10-24 | — | — | US | disclosed |
| US-6399604-B1 | ANXIETY, DOWN SYNDROME, SLEEP, COGNITIVE AND SEIZURE DISORDERS, AND OVERDOSE WITH BENZODIAZEPINE DRUGS | NEUROGEN CORPORATION | 2002-06-04 | — | — | US | disclosed |
| US-6143760-A | Substituted 4-oxo-napthyridine-3-carboxamides: GABA brain receptor ligands | NEUROGEN CORPORATION (US) | 2000-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156280-A1 | Substituted 4-oxo-napthyridine-3-carboxamides: GABA brain receptor ligands | GABRA4, GABRA1, GABRA2 | EPHX2 2928/4885LOXL2 2831/4885ABCB1 391/4885 |
| US-20240182382-A1 | ALIPHATIC 18F-RADIOLABELING OF A TETRAZINE PRECURSOR | NBAS, HRAS, NAA15 | EPHX2 1067/4885LOXL2 1240/4885ABCB1 2911/4885 |
| US-20120022109-A1 | OXADIAZOLE DERIVATIVES | OXA1L, HLA-DRB1, SSB | EPHX2 2340/4885LOXL2 1771/4885ABCB1 1198/4885 |
| US-20120035226-A1 | OXADIAZOLE DERIVATIVES | OXA1L, HLA-DRB1, SSB | EPHX2 2340/4885LOXL2 1771/4885ABCB1 1198/4885 |
| US-20240166612-A1 | ARYLTHIOETHER ACETAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | AGXT, AADAC, AGPAT2 | EPHX2 381/4885LOXL2 305/4885ABCB1 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.